We performed an economic analysis of data from 180 women in a clinical trial of conventional-dose chemotherapy vs high-dose chemotherapy plus stem-cell transplantation for metastatic breast cancer responding to first-line chemotherapy. Data on resource use, including hospitalizations, medical procedures, medications, and diagnostic tests, were abstracted from subjects' clinical trial records. Resources were valued using the Medicare Fee Schedule for inpatient costs at one academic medical center and average wholesale prices for medications. Monthly costs were calculated and stratified by treatment group and clinical phase. Mean follow-up was 690 days in the transplantation group and 758 days in the conventional-dose chemotherapy group. Subjects in the transplantation group were hospitalized for more days (28.6 vs 17.8, P=0.0041) and incurred higher costs (US dollars 84055 vs US dollars 28169) than subjects receiving conventional-dose chemotherapy, with a mean difference of US dollars 55886 (95% CI, US dollars 47298-US dollars 63666). Sensitivity analyses resulted in cost differences between the treatment groups from US dollars 36528 to US dollars 75531. High-dose chemotherapy plus stem-cell transplantation resulted in substantial additional morbidity and costs at no improvement in survival. Neither the survival results nor the economic findings support the use of this procedure outside of the clinical trial setting.
Download full-text PDF |
Source |
|---|---|
| http://dx.doi.org/10.1038/sj.bmt.1703795 | DOI Listing |
Publication Analysis
Top Keywords
Similar Publications
Low-Dose Anti-PD(L)1 for the Treatment of Solid Malignancies.
JCO Glob Oncol
November 2024
Division of Medical Oncology, Hospital de Base-FUNFARME, São José do Rio Preto, Brazil.
Article Synopsis
- - This study examines whether lower doses of anti-PD(L)1 agents are as effective as the standard doses for treating patients with solid tumors at a Brazilian hospital, aiming to highlight cost-effectiveness.
- - A total of 71 patients were analyzed, comparing efficacy outcomes such as clinical overall response rate, progression-free survival, and overall survival between those receiving low-dose (LD) and conventional-dose (CD) treatments.
- - Findings revealed no significant differences in treatment outcomes between LD and CD groups, suggesting that lower doses could provide a more accessible treatment option worth further investigation in future randomized trials.
Dose Optimization of Fluconazole After Initial Treatment Failure in Pulmonary Cryptococcosis in an Obese Patient with Type 2 Diabetes and Cirrhosis: A Case Report.
Infect Drug Resist
November 2024
Department of Pharmacy, Tongji Hospital, Tongji Medical College, Huazhong University of Science and Technology, Wuhan, People's Republic of China.
Background: Pulmonary cryptococcosis is a fungal infection of the lungs, particularly challenging to treat in patients with multiple comorbidities such as obesity, type 2 diabetes, and cirrhosis. Fluconazole is a first-line medication for the treatment of pulmonary cryptococcosis, but currently there is a lack of clinical medication experience in obese patients with multiple comorbidities, especially in dose adjustment after treatment failure.
Case Introduction: This case report describes the experience of fluconazole in the treatment of pulmonary cryptococcal infection in a 45-year-old Chinese male with obesity, type 2 diabetes, and cirrhosis.
Intensified alkylating chemotherapy for patients with oligometastatic breast cancer harboring homologous recombination deficiency: Primary outcomes from the randomized phase III OLIGO study.
Eur J Cancer
December 2024
Department of medical oncology, NKI-AVL, Amsterdam, the Netherlands; Department of medical oncology, Amsterdam University Medical Center, Amsterdam, the Netherlands. Electronic address:
Background: Oligometastatic breast cancer (OMBC) is a clinical entity with a prospect of long-term survival, but uncertainty remains on its optimal treatment. We studied whether intensified alkylating chemotherapy (IACT) improves long-term outcome compared to conventional-dose chemotherapy (CDCT) as part of a multimodality approach for patients with OMBC harboring homologous recombination deficiency (HRD).
Patients And Methods: Eligible patients had HER2-negative OMBC, harboring HRD, with ≤ 3 distant metastases, pathologic proof of distant disease and a favorable response to three cycles CDCT.
Effectiveness and safety of lower dose sulfamethoxazole/trimethoprim for Pneumocystis jirovecii pneumonia prophylaxis in patients with systemic rheumatic diseases receiving moderate-to high-dose glucocorticoids.
Respir Investig
November 2024
Department of Rheumatology, Seirei Hamamatsu General Hospital, 2-12-12 Chuo-ku, Sumiyoshi, Hamamatsu, Shizuoka, 430-8558, Japan.
Article Synopsis
- The study aimed to compare the effectiveness and safety of low-dose sulfamethoxazole/trimethoprim (SMX/TMP) for preventing Pneumocystis jirovecii pneumonia (PCP) in patients with systemic rheumatic disease (SRD) on glucocorticoids.
- A total of 186 Japanese patients were analyzed, with no cases of PCP reported in either the low-dose or conventional-dose groups after one year, although two in the low-dose needed an increased dose.
- The results indicated that low-dose SMX/TMP was as effective as conventional dosage for PCP prevention while resulting in lower discontinuation rates and fewer severe adverse drug reactions.
Neoadjuvant sunitinib plus exemestane in post-menopausal women with hormone receptor-positive/HER2-negative early-stage breast cancer (SUT_EXE-08): a phase I/II trial.
Sci Rep
October 2024
Breast Cancer Unit, Department of Medical Oncology, Catalan Institute of Oncology (ICO), L'Hospitalet de Llobregat, Barcelona, Spain.
Article Synopsis
- * Out of 18 postmenopausal women treated, 66% showed an objective response, and common side effects included fatigue and hypertension, but no severe toxicities were reported.
- * The research also highlighted changes in biomarker levels and gene expression after treatment, indicating potential biological impacts of combining antiangiogenic therapy with hormone therapy in this patient population.
Want AI Summaries of new PubMed Abstracts delivered to your In-box?
Enter search terms and have AI summaries delivered each week - change queries or unsubscribe any time!